(42% each). Most of the subjects had not received previous chemotherapy (67%), radiotherapy (83%), or radiosurgery (87.5%). Of the 21 patients that finished the study, 42% showed partial response (8% complete response), 33% improved their performance status, and 33% improved their neurological functional status. The median time to progression was 204 days. The proportion of surviving patients was 0.816 at 99 days and 0.497 at 180 days. As for toxicity, 8% of patients suffered grade III asthenia, and 4% suffered grade III thrombocytopenia.
Conclusions: The treatment of brain metastasis with temozolomide as concomitant treatment is associated to a 50% survival at six months, and a low degree of grade III toxicity.

9111 POSTER

Pathology-validated automated volumetric tumour segmentation in 4D-PET vs 3D-PET of NSCLC

L. Boersma[1], J. van Loon[1], A. van Baardwijk[1], C. Siedschlag[2], R.J. van Suylen[3], M. Rossi[4], J. Blaauwgeers[5], H. Klomp[6], J. Stroom[4], K. Gilhuijs[2]. [1]*Maastricht University Medical Center, Department of Radiation Oncology (MAASTRO), Maastricht, The Netherlands;* [2]*The Netherlands Cancer Institute, Department of Radiology, Amsterdam, The Netherlands;* [3]*Maastricht University Medical Center, Department of Pathology, Maastricht, The Netherlands;* [4]*The Netherlands Cancer Institute, Department of Radiotherapy, Amsterdam, The Netherlands;* [5]*Onze Lieve Vrouwe Gasthuis, Department of Pathology, Amsterdam, The Netherlands;* [6]*The Netherlands Cancer Institute, Department of Surgery, Amsterdam, The Netherlands*

Background: It has been recommended to use a 42% threshold of maximum intensity to automatically delineate the primary lung tumor on a 3D ^{18}F-FDG-PET scan. However, for radiation treatment planning, 4D-PET scanning is increasingly being used. It is unknown whether the threshold recommended for 3D scans also applies to 4D scans. The aim of the current study was to compare the size of a primary lung tumor on 3D- vs 4D-PET as measured at the 42% threshold level, and to compare these sizes with the gold standard, being the size at pathology.
Methods and Material: 3D- and 4D-PET scans were obtained in 6 patients with NSCLC prior to surgery. The GTV was automatically determined using a 42% threshold level on both the 3D-PET and all 8 respiration phases of the 4D-PET. For the 4D-PET an average volume with standard deviation (SD) was calculated over the 8 phases for each patient. At pathology, the lung lobe was inflated with formalin. The fixated specimen was sectioned in parallel slices of approximately 5 mm, orthogonal to the longest axis. Digital photographs were obtained. About 40 microscopic sections per patient were analyzed encompassing the complete tumor. The area of the tumor on each slice was calculated, and multiplied with the slice thickness to derive the pathologic tumor volume. Both pathologic and PET volumes were converted to an effective diameter (ED) of the GTV, using: ED $((\text{volume} * \frac{3}{4} * (1/p))^{\frac{1}{3}})*2$. Finally, for both the 3D- and the 4D-PET, we calculated the ideal threshold level for each tumor by establishing the threshold value that yielded the volume closest to the pathologic volume.
Results: The ED of the 3D-PET overestimated the pathologic ED (28.4 mm$\pm$15.0 vs 24.4 mm$\pm$16.2, p = 0.046). Only a trend was observed regarding the overestimation of the ED with 4D-PET averaged over all phases compared to pathology (26.7 mm$\pm$14.1 vs 24.4 mm$\pm$16.2, p = 0.063). The ED varied also per respiratory phase, as indicated by the SD over the phases per patient (range: 0.37−2.6 mm). The ideal threshold level for the 4D-PET was 49.8%$\pm$7.8% on average for all phases, and 53%$\pm$8.1% for the 3D-PET. The variation in threshold values between the 4D-PET phases was of the same order of magnitude (range of SD: 0.9−5.8%).
Conclusions: For automatic thresholding of the volume of primary lung tumors on FDG-PET, different threshold levels should be used for 3D- vs 4D-PET. Data of more patients will be analyzed to investigate the optimal method for automatic delineation of lung tumors in 4D-PET.

9112 POSTER

Stereotactic body radiation therapy for peripheral lung tumours: a study in a French cancer center

L. Claude[1], N. Hau[1], I. Martel-lafay[1], C. Carrie[1], M. Ayadi[1], F. Gassa[1]. [1]*Centre Regional Leon Berard, Radiotherapy, Lyon, France*

Background: The efficiency of Stereotactic Body Radiation Therapy (SBRT) in thoracic tumours becomes well known, while the evaluation of related toxicities is less described. A follow-up of all the pts treated in a French cancer center is described, focusing on the toxicity.
Patients and Methods: From June 2007 to December 2008, 31 pts, median 72 y. [54−86], were treated with SBRT for pulmonary tumour. 23 pts were treated for non-operated peripheral non small cell lung cancer (NSCLC), 3 pts for solitary metastasis (NSCLC n = 2, rectal cancer n = 1) and 5 pts for tumour of doubtful origin (NSCLC-solitary late metastasis of known cancer). 20 pts had histologicaly or cytologicaly proven tumour; in 11 cases, the diagnosis was retained without histological proof if tumour size increased or tumour was highly positive in PET-TDM without argument for another cause. SBRT was performed because of refusal of surgery (n = 1), or contraindications for surgery in 30 pts (comorbidities n = 24, previous surgery n = 6). Median forced expiratory volumes in 1 s (FEV1) before SBRT was 1.6 l [0.48−3.06]. Patients were immobilized in a Stereotactic Body Frame^{TM}. Breathing motion was limited with abdominal compression. Patients were treated with image guidance using Cone-Beam computed tomography before each fraction. 4 fractions of 10 Gy (n = 4), 12 Gy (n = 12) or 15 Gy (n = 13) or 8 fractions of 5 Gy (n = 2) were delivered on the 70% isodose (n = 28), 80% (n = 2) or 95% (n = 1) in 2 weeks, using 10−12 fields.
Results: With a median follow up of 13 months [2−32], 26 pts were alive and 5 had died (2 unknown causes without argument for toxic death, 3 metastatic progressions). Local control at 6 months was obtained for 26 on 28 evaluable pts (92%). During RT, asthenia gr.2 (n = 1), dyspnoea gr.2 (n = 1) and cough gr.2 (n = 1) were noticed. 29 pts were evaluated for acute toxicity (<3 months after the end of SBRT) while 2 pts had died before. 1 dermatitis (gr.2) was reported. After 3 months, 3 pts dyspnoea from gr. 3 to gr.4 (n = 3), from gr.2 to gr.4 (n = 1), and from gr.1 to gr.2 (n = 1), with images compatible with localized radiation pneumonitis on TDM in 3 pts (gr.2−3). No other toxicity was reported. Dosimetric studies for these pts will be presented.
Conclusion: SBRT for thoracic tumours is efficient and well tolerated. It is usually performed in high-risk pts suffering from severe comorbidities but indications must be carefully weighted against the risk of median-term toxicity, in particular for pulmonary function.

9113 POSTER

Palliative radiation oncologic therapy in lung cancer with superior vena cava syndrome

P. Kara[1], I. Ugur[1], C. Misirlioglu[1], T. Demirkasimoglu[1], E. Sanri[1], Y. Elgin[1], A. Ozgen[1], T. Yurukoglu[1], N. Ozdamar[1], Y. Guney[1]. [1]*Ankara Oncology Research and Education Hospital, Radiation Oncology, Ankara, Turkey*

Background: Lung cancer is the most common cause of superior vena cava syndrome (SVCS) and requires timely recognition and management. Radiotherapy is a succesfully proven, feasible and appropriate antineoplastic treatment for the palliation of this oncologic emergency. In order to study clinical profile of lung cancer with SVCS were studied retrospectively.
Patients and Methods: All lung cancer patients who presented with SVCS during last five years were studied. All 213 patients with SVCS with lung cancer; 194 (91%) male and 19 (9%) female. Age distrubutions were between 35−82 and most patients were in 5. And 6. decade (female median age 44, male 61). Neck edema was found in 177 (83%) patients, 112 (52.5%) had collateral veins and severe dyspnea, cough found in 123 (57.7%) and severe dyspnea were found in all patients. Localization of lesions were right in 188 (88.26%) and left in 25 (11.74%) of cases. Twenty seven were small cell lung cancer (18 disseminated, 9 localized) and 167 (78.40%) were nonsmall cell histology (44 epidermoid, 16 adenocarcinoma, 3 large cell and others nonclassified) and 19 (8.92%) patients were radiologically diagnosed and treated as emergency. According to TNM stage; 37 (17.37%) were in IIIB, 88 (41.34%) were in stage IV and 88 (41.34%) stage not stratified. Cough and dyspnea decreased in 55% of patients. Thirty four patients were died during therapy, 44% were dead in six mounths and only 1 year overall survival rate was 15.6%.
Conclusions: Radiotherapy is effective for paliation in SVCS with lung cancer; in our cases increased amount of patients needed radiotherapy as a firsth treatment especially in nonlocalized group. Nearly 10% of patients were female as an increasing proportion. Overall survival of patients were very poor and symptom control and increasing life quality is important but multimodality new treatments necessary for increasing life span of patients

9114 POSTER

Malignant pleural mesothelioma: the prognostic significance of different surgical treatments. A retrospective study from a single-institution experience

E. Ruffini[1], P.L. Filosso[1], D. Mirabelli[2], S. Asioli[3], L. Buffoni[4], M. Schena[4], M.C. Bruna[1], A. Oliaro[1]. [1]*University of Torino, Thoracic Surgery, Torino, Italy;* [2]*University of Torino, Epidemiology, Torino, Italy;* [3]*University of Torino, Pathology, Torino, Italy;* [4]*AOU S. Giovanni Battista, Medical Oncology, Torino, Italy*

Backgrounds: Optimal therapy in patients with Malignant Pleural Mesothelioma (MPM) is a matter of debate. Many authors questioned the role of